“SepTec is a patent pending screening tool that can definitively identify specific sepsis pathogens directly from an unpurified blood sample in minutes”
Sepsis is the body’s life-threatening immune response to the presence of bacteria in the blood or other infection and can claim lives within hours. SepTec’s exclusive approach is designed to achieve more rapid and automated pathogen identification in minutes, not hours. The technology can detect sepsis associated pathogen’s in whole blood within 15 minutes.
SepTec is based out of from Dublin City University (DCU) and currently on its second Enterprise Ireland Commercialisation Fund (2016-2018). It is supported by an exceptional team of electrochemists, biologists, engineers and clinical key opinion leaders, including Dr. Elaine Spain, Dr. Kellie Adamson and Prof. Robert Forster are currently driving the commercialisation of the SepTec technology..
The device is currently undergoing proof of concept in collaboration with St. James’s Hospital and Beaumont Hospital. The device is being validated using spiked blood from healthy volunteers, sepsis positive blood culture samples and blood samples drawn directly from patients with suspected sepsis.
The first application of this core technology will target the Sepsis Diagnostics & Blood Culture Test market (valued at $3.01Bn), with the goal of commercialising an innovative sepsis diagnostic device that offers a rapid, simple solution.
The space is dominated by a small number of large global MNCs, including Roche, T2 Biosystems, Seegene and Molzym who offer specific pathogen identification and analysis times ranging from 5 hours to 2 days. SepTec strongly positions itself as a well-differentiated product from its competitors, namely by speed, accuracy and reduced cost”.